Dragonfly Therapeutics appointed Dr. Asya Grinberg as Head of Biologics

Dragonfly Therapeutics announced that they have appointed Dr. Asya Grinberg to its senior team as Head of Biologics.

Dr. Grinberg spent 12 years at Acceleron Pharma discovering and developing novel protein therapeutics for treatment of hematopoietic diseases and cancer. She most served as Senior Director of Cell Biology and Protein Chemistry and has been a strong scientific and strategic driver of internal innovation. Dr. Grinberg’s efforts were instrumental to the development of five clinical candidates, including Luspatercept (currently in Phase III testing) for treatment of beta-thalassemia and MDS. Dr. Grinberg is the key inventor of the IntelliTrap drug discovery platform targeting the TGF-beta superfamily. Dr. Grinberg received her M.Sc. in Bioorganic Chemistry from Moscow State University and did her Ph.D. studies at Max Delbrück Centre for Molecular Medicine in Germany. She completed her post-doctoral fellowship at the University of Michigan supported by the at Howard Hughes Medical Institute. Dr. Grinberg is a co-author of more than 40 scientific publications, and co-inventor on a number of patents.

Dragonfly co-founder and CEO, Bill Haney said that they are thrilled to welcome Dr. Grinberg to Dragonfly. Her depth of understanding of protein therapeutics, coupled with her talent for innovation, will accelerate their development of novel cancer therapies, which use Natural Killer cells to both enhance the effectiveness of T cell performance and attack cancer directly.